REPROBESITY

Search for new therapeutic agents against complicated obesity by reprofiling existing drugs

 Coordinatore FUNDACION PUBLICA ANDALUZA PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD 

 Organization address address: AVENIDA JORGE LUIS BORGES 15
city: MALAGA
postcode: 29010

contact info
Titolo: Dr.
Nome: Fernando
Cognome: Rodriguez De Fonseca
Email: send email
Telefono: 34951030446
Fax: 34951239191

 Nazionalità Coordinatore Spain [ES]
 Sito del progetto http://www.reprobesity.eu/
 Totale costo 6˙946˙279 €
 EC contributo 5˙399˙412 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2007-B
 Funding Scheme CP-TP
 Anno di inizio 2008
 Periodo (anno-mese-giorno) 2008-12-01   -   2012-05-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    FUNDACION PUBLICA ANDALUZA PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD

 Organization address address: AVENIDA JORGE LUIS BORGES 15
city: MALAGA
postcode: 29010

contact info
Titolo: Dr.
Nome: Fernando
Cognome: Rodriguez De Fonseca
Email: send email
Telefono: 34951030446
Fax: 34951239191

ES (MALAGA) coordinator 0.00
2    ALMA MATER STUDIORUM-UNIVERSITA DI BOLOGNA

 Organization address address: Via Zamboni 33
city: BOLOGNA
postcode: 40126

contact info
Titolo: Dr.
Nome: Alessandra
Cognome: Malavolta
Email: send email
Telefono: +39 051 20 99338
Fax: +39 051 2099379

IT (BOLOGNA) participant 0.00
3    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

 Organization address address: 101 Rue de Tolbiac
city: PARIS
postcode: 75654

contact info
Titolo: Dr.
Nome: Giovanni
Cognome: Marsicano
Email: send email
Telefono: 33557573657
Fax: 33557573669

FR (PARIS) participant 0.00
4    JOHANNES GUTENBERG UNIVERSITAET MAINZ

 Organization address address: SAARSTRASSE 21
city: MAINZ
postcode: 55099

contact info
Titolo: Prof.
Nome: Beat
Cognome: Lutz
Email: send email
Telefono: 4961310000000
Fax: 4961310000000

DE (MAINZ) participant 0.00
5    UNIVERSIDADE DE SANTIAGO DE COMPOSTELA

 Organization address address: "PAZO DE SAN XEROME, PRAZA DO OBRADOIRO S/N"
city: SANTIAGO DE COMPOSTELA
postcode: 15782

contact info
Titolo: Dr.
Nome: Fernando
Cognome: Sedano Arnaez
Email: send email
Telefono: +34 981 547050
Fax: +34 981 528019

ES (SANTIAGO DE COMPOSTELA) participant 0.00
6    UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ

 Organization address address: Langenbeckstrasse 1
city: Mainz
postcode: 55131

contact info
Titolo: Dr.
Nome: Uta
Cognome: Veith
Email: send email
Telefono: +49 613 117 9717
Fax: +49 613 117 9669

DE (Mainz) participant 0.00
7    VIVIA BIOTECH S.L.

 Organization address address: C SANTIAGO GRISOLIA 2 OFICINA 205
city: TRES CANTOS MADRID
postcode: 28760

contact info
Titolo: Ms.
Nome: Olivia
Cognome: De La Lama Noriega
Email: send email
Telefono: +34 679 324769
Fax: +34 951291447

ES (TRES CANTOS MADRID) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

phenotyped    barrier    extracted    cells    patients    anti    cannabinoid    rimonabant    abdominal    biomarkers    obese    obesity    indications    fat    drugs    profiles    discover    drug    above    approved    orphamed    safety   

 Obiettivo del progetto (Objective)

'Obesity is one of the most serious and fast-growing health problem in the European Union, and a leading cause of diabetes. The main barrier for approval of an anti-obesity drug is the safety requirements. We propose to overcome this barrier by discovering phenotypes and biomarkers that identify subsets of patients with safe and efficacious responses to drugs, and by identifying new indications of existing drugs with proven safety profiles. To be approved, anti-obesity drugs need to show a decrease in abdominal fat. We focus on approaches targeting directly abdominal fat cells. In the last years only the cannabinoid CB1 receptor antagonist Rimonabant has been approved as a therapeutic agent to combat complicated obesity. Research performed with this drug has clearly revealed a role for the endogenous cannabinoid system in controlling energy homeostasis. However, its utility is limited to a restricted set of patients. A new phenotype and/or biomarker may identify responsive patients with good safety profiles. This proposal aims to discover novel or improved treatments in the shortest possible timeframe through three synergistic Specific Aims: 1) Clinical phenotyping of obese patients to identify those that would benefit from existing therapies such as Rimonabant. 2) Discover biomarkers for subsets of obese patients that may correlate with therapeutical outcomes. These biomarkers will be discovered by a novel approach called Combinatorial Cytomic Biomarkers developed by OrphaMed, applied to cells from two physiologically interlinked sources: blood and abdominal-fat samples, extracted from the above phenotyped patients. 3) Identify new indications of existing drugs, alone or in combination, with potential anti-obesity efficacy by lowering the fat content and the glucose uptake of abdominal fat cells, which would be expected to improve carbohydrate/lipid metabolism and lower body weight, extracted from the above phenotyped patients. This will be accomplished by screening approximately 2.000 known drugs against these fat cells using the novel technology platform “ExviTech” from OrphaMed. Candidates would be evaluated in animal models of obesity.'

Altri progetti dello stesso programma (FP7-HEALTH)

NEUROGRAFT (2012)

Development of Functionalised Cell Seeded Bioartificial Organ for Transplantation in Nerve Repair

Read More  

EDUFLUVAC (2013)

Combinatorial immunization strategy to educate the immune system towards cross recognition and coverage against antigenic drift in seasonal influenza virus exposure

Read More  

HEALTH PROMETHEUS (2009)

HEALTH PROfessional Mobility in THe European Union Study

Read More